Abstract

Coronary artery disease in Asia is the leading cause of heart failure and is associated low quality of life with poor survival, despite advances in medical therapy. Treating the coronary arteries to improve blood supply (revascularisation) has long been considered as a treatment option. Stent thrombosis (incidence is 0.5-2 %,) is abrupt vessel closure, is one of the fatal complications of percutaneous coronary intervention. The common risk factors include a history of Type 2 diabetes mellitus, acute coronary syndrome, and reduced left ventricular ejection fraction. Drug eluting stents (Zotarolimus and Everolimus eluting stents) are very less likely to cause restenosis, as they are considered for their durable efficacy. DAPT ( Dual antiplatelet therapy ) is usually prescribed after a heart attack or stent placement to keep the vessels patent and to prevent future heart attacks for period of 12 months, whereas 6 months duration can be considered for those with high bleeding risk. In the first year following PCI, ticagrelor or prasugrel are associated with fewer gastrointestinal bleeds events than clopidogrel which is not perfect match as compared to new options.